Pherecydes Pharma Announces Its 2020 Annual Financial Results and Confirms Its 2021 Outlook Regulatory News:
Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces its annual results for the year to December 31, 2020 and confirms its development prospects for 2021.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, states: “
Thanks to the resounding success of our Initial Public Offering, we are accelerating the strategic investments in our R&D and clinical programs. This ramping up is being accompanied by an ongoing very active intellectual property policy that has recently led to the granting of two
Pherecydes Pharma Announces Its 2020 Annual Financial Results and Confirms Its 2021 Outlook pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
A Preclinical Trial Demonstrates the Benefits of Inhaled Pherecydes Pharma Phages in Treating Ventilation-Associated Pneumonia
th Annual Inhalation and Respiratory Drug Delivery Congress (April 20-21, 2021)
Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that Nathalie Heuzé-Vourc h of the
Centre d Etude des Pathologies Respiratoires (Research Center for Respiratory Diseases) (UMR INSERM-Université de Tours U1100) will present the results of a preclinical study undertaken with the phages of Pherecydes Pharma at the
6
The presentation, entitled
Inhaled phage therapy to treat Ventilation Associated Pneumonia